RPG Life Sciences Limited · NSE:RPGLIFE
RPG Life Sciences — H1 FY2027 Earnings Presentation
30 slides from RPG Life Sciences's earnings presentation, 2026
Slide 1: FY27: Q2 & H1 Performance
FY27: Q2 &H1 Performance RPG Life Sciences Investors’ Presentation 1
Slide 2: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 3: RPG Group: Powered by Passion, Driven by Ethics
RPG Group: Powered by Passion, Driven by Ethics RPG Enterprises was founded in 1979. The group currently operates various businesses in Infrastructure, Technology, Life Sciences, Plantations and Tyre industries. The group has business history dating back to 1820 AD in banking, textiles, jute and tea
Slide 4: RPGLS Company Overview
RPGLS Company Overview 4
Slide 5: RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences: An Integrated Pharmaceutical Company RPG Life Sciences is an integrated 50+ years REVENUE MIX pharmaceutical company operating in the of Rich Legacy BY CATEGORIES Domestic and International markets in the Branded Formulations, Global Generics, 18% and Synthetic APIs 63+ countries
Slide 6: Board of Directors
Board of Directors • Experienced professionals and industry veterans from various sectors, including pharmaceuticals, business management, and corporate governance. • The board has specialized committees, such as the Audit Committee, Corporate Social Responsibility (CSR) Committee, and the Nominatio
Slide 7: Product Portfolio, Textbook brands; focus on chronic & specialty therapies
RPG Life Sciences: Product Portfolio, Textbook brands; focus on chronic & specialty therapies Key Therapies DF Key Products Legacy Portfolio Nephrology Immunosuppressants Rheumatology Textbook Brands New Portfolio Oncology Specialty Pain Management Chronic Life cycle Gastroenterology Management IF K
Slide 8: 50+ years of RPGLS journey- A snapshot
50+ years of RPGLS journey- A snapshot Received Naprosyn ANDA approval in Canada Launched Urolife & 2026 acquired 9 brands from Sun Pharma 2025 2019 Formed RPGAP, a dedicated API subsidiary of RPGLS Demerger of the 2016 and acquired 2 API pharmaceutical Entered the Anti- Diabetic therapy businesses
Slide 9: External Awards & recognition
External Awards & recognition Recognised for excellence in innovation, commercial performance and responsible business practices Leading Nephrology Excellence in Breakthrough Best Use of AI in Leading Mid Corporates Company-2026 Pharmaceutical Innovations Sales Force Effectiveness of India- 2025 Ind
Slide 10: Our Business Segments
Our Business Segments 10
Slide 11: Domestic Formulations: Overview and Strategy
Business Overview Pan-India presence Established brands Strong therapy presence Diverse portfolio Reach to over 1 lakh doctors Across chronic, sub-chronic Azoran, Aldactone, Lomotil, Cardiology, diabetes, urology, and 3000+ stockiest and acute segment Naprosyn, Serenace, Norpace nephrology, rheumato
Slide 12: Domestic Formulations: Key performance highlights
Domestic Formulations: Key performance highlights 4th fastest 12 ranks ₹100 cr Growing company Jump in market Naprosyn crosses among Top 50 in IPM1 rank since Mar’25 the milestone in secondary sales DF H1 growth at 13.0%; 1.2 Up from Rank 62 in Mar’25 to Flagship brand, 50+ years of times faster tha
Slide 13: Manufacturing facilities for domestic and international formulations
Manufacturing facilities for domestic and international formulations F1 Unit • Serves domestic and 20+emerging markets, ensuring global accessibility • State-of-the-art multipurpose plant with dedicated lines for oral dosage forms – tablets, liquids, and powders • Installed capacity of 177 crore tab
Slide 14: API & Intermediates Business: Overview and Strategy
Business Overview 50+ Markets served 490 KL capacity 3 Manufacturing units Strong Approvals API & US, Europe, LATAM, Asia Pacific & MENA regions Combined API & Intermediates capacity Located in Navi Mumbai, Hyderabad & Vizag WHO GMP, TGA Australia, PMDA Japan Intermediates Business : Three pillars t
Slide 15: API business transitions into a dedicated subsidiary called RPGAP
API business transitions into a dedicated subsidiary called RPGAP Strategic investments and acquisitions are expanding the API platform's capabilities and manufacturing footprint 1. Formed a dedicated API 2. Strategic capital commitment subsidiary • RPG Active Pharma • Strategic PE, InvAscent establ
Slide 16: API & Intermediates manufacturing facility
API & Intermediates manufacturing facility Navi Mumbai Plant • Three specialized units • MF1: multipurpose unit serving emerging markets, including India. • MF2: dedicated immunosuppressant facility for regulated and emerging markets. • MF3: multipurpose unit for regulated and emerging markets • Ins
Slide 17: International Formulations: Overview and Strategy
Business Overview 50+ Markets served 5 Therapy 2 Manufacturing units Strong Regulatory presence Track Across Europe, UK, Canada, Immunosuppressant, Cardio, Located in Ankleshwar, TGA Australia, EU GMP, Australia, Southeast Asia, International Neuro, Gastro & Uro Gujarat Health Canada, Zazibona, Lati
Slide 18: Financial Performance
Financial Performance 18
Slide 19: Q2 FY27 Financial Performance Update
Q2 FY27 Financial Performance Update: Revenue up by 16.2% with improved profitability (All figures in Rs. Crores) Figures in circle are Margins Revenue from Operations Adjusted EBITDA & EBITDA Margin +16.5% +15.0% 211.6 50.1 181.7 43.6 24.0% 23.7% 17.5% Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Adjusted PBT &
Slide 20: Q2 FY27: Business segment wise performance
Q2 FY27: Business segment wise performance (All figures in Rs. Crores) Domestic International API1 Formulations Formulations (13% of sale) (69% of sale) (18% of sale) +11.6% +6.4% +89.2% 145.7 34.5 36.7 28.0 130.6 14.8 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 1. API Q2 FY27 sales include 0.5
Slide 21: H1 FY27 v/s H1 FY26: Financial Performance Update
H1 FY27 v/s H1 FY26: Financial Performance Update (All figures in Rs. Crores) Figures in circle are Margins Revenue from Operations Adjusted EBITDA & EBITDA Margin +16.2% +16.1% 407.3 97.9 350.6 84.3 24.0% 24.0% 17.5% H1 FY26 H1 FY27 H1 FY26 H1 FY27 Adjusted PBT & PBT Margin Adjusted PAT & PAT Margi
Slide 22: H1 FY27: Business segment wise performance
H1 FY27: Business segment wise performance (All figures in Rs. Crores) Domestic International API1 Formulations Formulations (14% of sale) (69% of sale) (17% of sale) +13.0% +7.0% +58.5% 278.3 67.0 71.7 54.6 246.2 34.5 H1 FY26 H1 FY27 H1 FY26 H1 FY27 H1 FY26 H1 FY27 1. API H1 FY27 sales include 0.5
Slide 23: RPG Life Sciences' Market Capitalisation Rises 64% in H1 FY27
RPG Life Sciences’ Market Capitalisation Rises 64% in H1 FY27 Significantly outperforming the Sensex and BSE Healthcare Index RPGLS market cap, ₹ cr Market-outperformance 64% 5,023 cr. BSE Sensex growth at only 1%, BSE Healthcare Index growth at 20% in the same period 3,072 cr. Trading at a P/E rati
Slide 24: Other key highlights
Other key highlights 24
Slide 25: Digital Initiatives: Manufacturing and Quality
Digital Initiatives: Manufacturing and Quality Digital Retina Intelligent Chilling IOT based AHU Power Management Scanner Plant Manager monitoring system System • Biometric Access with IRIS/ Retina • Operates Pumps & Scanner enables • Implementation of Utility Asset Chillers according • Safe, reliab
Slide 26: AI Initiatives: Embedding intelligence across the business
AI Initiatives: Embedding intelligence across the business AI-Enabled Customer Engagement Smarter Commercial Decision-Making • RPGserv is an AI-enabled digital • GenAI-powered campaign dashboards and doctor-support platform enhancing data analysis physician engagement through • RXR 3.0: Salesforce t
Slide 27: Happiness initiatives: Engaging teams beyond work
Happiness initiatives: Engaging teams beyond work Building connection, celebrating traditions and creating shared experiences Independence Day Celebrations Festival Celebrations Employee Engagement Moments of national pride & unity Celebrating our diverse traditions Strengthening teamwork through fu
Slide 28: Journey Ahead
Journey Ahead 29
Slide 29: RPGLS Journey Ahead: strategic pillars of action
RPGLS Journey Ahead: 7 strategic pillars of action Portfolio Expand market Drive productivity, Integrate, Scale & Build the pipeline Strengthen Build critical development and reach, customer efficiency and Grow the API and expand into capacity, quality capabilities and mega-brands relationships and
Slide 30: Thank You
THANK YOU 31